Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 28Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Breast Neoplasms 22Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Carcinoma, Non-Small-Cell Lung 21Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hodgkin Disease 15Lymphoma, T-Cell, Cutaneous 13Glioblastoma 13Leukemia, Lymphocytic, Chronic, B-Cell 12Brain Neoplasms 12Recurrence 11Myelodysplastic Syndromes 11Mycosis Fungoides 11Lymphoma, B-Cell, Marginal Zone 11Leukemia 11Burkitt Lymphoma 11Neuroblastoma 10Neoplasms 10Sezary Syndrome 9Congenital Abnormalities 9Prostatic Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Squamous Cell Carcinoma of Head and Neck 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms, Plasma Cell 7

Interventions

Fulvestrant 19Letrozole 8Anastrozole 6Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Injections 4Goserelin 4Docetaxel 4pyrotinib 3exemestane 3trastuzumab deruxtecan 2toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2abemaciclib 2Vinorelbine 2Trastuzumab 2FCN-437c 2Everolimus 2Dasatinib 2Aromatase Inhibitors 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2vandetanib 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Breast Cancer × Vorinostat × Clear all
NCT00719875 2017-03-03

HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer

Yale University

Phase 1 Completed
24 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡